Ooops... Something went wrong while loading this page.
ANI Pharmaceuticals delivered strong Q4 and FY25 results, with revenue up 30% and record Cortrophin Gel growth. Read why ANIP stock is rated a hold.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results